An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Personalis, Inc. (NASDAQ: PSNL), a leader in cancer genomics, announced its participation at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 2:15 p.m. Eastern Time. This event highlights the company's innovation in precision cancer therapies and diagnostics through its Personalis NeXT Platform®, which analyzes all human genes and the immune system from a single sample. Personalis is committed to advancing cancer sequencing with a focus on clinical accuracy, quality, and efficiency.
Positive
None.
Negative
None.
MENLO PARK, Calif.--(BUSINESS WIRE)--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 2:15 p.m. Eastern Time.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis’ Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter.
When will Personalis present at the Needham Virtual Healthcare Conference?
Personalis will present at the Needham Virtual Healthcare Conference on April 13, 2022, at 2:15 p.m. Eastern Time.
What is the main focus of Personalis, Inc.?
Personalis focuses on advanced cancer genomics, providing precision cancer therapies and diagnostics.
What is the Personalis NeXT Platform?
The Personalis NeXT Platform® is designed to analyze approximately 20,000 human genes and the immune system from a single sample, aiding cancer sequencing.
What stock symbol represents Personalis?
The stock symbol for Personalis is PSNL.
Where can I find more information about Personalis?
More information about Personalis can be found on their official website at www.personalis.com.
